These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28675026)

  • 41. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
    Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
    Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
    Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
    Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.
    Kothari S; Ud-Din N; Lisi M; Coyle T
    J Med Case Rep; 2016 Jun; 10():176. PubMed ID: 27301488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
    Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
    [No Abstract]   [Full Text] [Related]  

  • 48. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Torossian A; Broin N; Frentzel J; Daugrois C; Gandarillas S; Saati TA; Lamant L; Brousset P; Giuriato S; Espinos E
    Haematologica; 2019 Jul; 104(7):1428-1439. PubMed ID: 30679328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
    Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
    Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
    Yan HH; Jung KH; Son MK; Fang Z; Kim SJ; Ryu YL; Kim J; Kim MH; Hong SS
    Oncotarget; 2014 Oct; 5(19):9150-68. PubMed ID: 25193856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
    Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
    Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
    Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
    Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
    Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.
    Karaca Atabay E; Mecca C; Wang Q; Ambrogio C; Mota I; Prokoph N; Mura G; Martinengo C; Patrucco E; Leonardi G; Hossa J; Pich A; Mologni L; Gambacorti-Passerini C; Brugières L; Geoerger B; Turner SD; Voena C; Cheong TC; Chiarle R
    Blood; 2022 Feb; 139(5):717-731. PubMed ID: 34657149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
    Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
    BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
    Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
    ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trial watch: success for crizotinib in ALK-driven cancer.
    Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119722
    [No Abstract]   [Full Text] [Related]  

  • 60. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.
    Ito M; Zhao N; Zeng Z; Chang CC; Zu Y
    Cancer Gene Ther; 2010 Sep; 17(9):633-44. PubMed ID: 20448669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.